Frost Eleanor, Hofmann Jonathan N, Huang Wen-Yi, Parks Christine G, Frazer-Abel Ashley A, Deane Kevin D, Berndt Sonja I
Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA 94305, USA.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Cancers (Basel). 2023 Oct 31;15(21):5231. doi: 10.3390/cancers15215231.
Immune dysregulation is thought to increase the risk of non-Hodgkin lymphoma (NHL), but the evidence varies by subtype. We evaluated whether antinuclear antibodies (ANA), double-stranded DNA antibodies (anti-dsDNA), and extractable nuclear antigen antibodies (anti-ENA) were associated with the risk of common NHL subtypes in a nested case-control study. The autoantibodies were tested in serum collected years prior to NHL diagnosis in 832 cases and 809 controls from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Logistic regression was used to determine odds ratios (ORs) and 95% confidence intervals (95% CI) for the association with NHL risk. No association was observed between ANA positivity and NHL risk overall (OR: 1.18, 95% CI: 0.88-1.58); however, ANA positivity was associated with an increased risk of diffuse large B-cell lymphoma (DLBCL) (OR: 1.83, 95% CI: 1.15-2.91), with 19.7% of cases and 12.2% of controls testing positive. The presence of either anti-ENA or anti-dsDNA was associated with an increased risk of NHL (OR: 2.93, 95% CI: 1.18-7.28), particularly DLBCL (OR: 3.51, 95% CI: 1.02-12.0) and marginal zone lymphoma (OR: 8.86, 95% CI: 1.26-62.0). Our study demonstrates that autoantibodies are associated with an elevated risk of DLBCL, providing support for autoimmunity as a risk factor.
免疫失调被认为会增加非霍奇金淋巴瘤（NHL）的风险，但证据因亚型而异。在一项巢式病例对照研究中，我们评估了抗核抗体（ANA）、双链DNA抗体（抗dsDNA）和可提取核抗原抗体（抗ENA）是否与常见NHL亚型的风险相关。对来自前列腺、肺、结直肠癌和卵巢癌筛查试验的832例NHL病例和809例对照在NHL诊断前数年采集的血清进行了自身抗体检测。采用逻辑回归确定与NHL风险相关的比值比（OR）和95%置信区间（95%CI）。总体而言，未观察到ANA阳性与NHL风险之间存在关联（OR：1.18，95%CI：0.88-1.58）；然而，ANA阳性与弥漫性大B细胞淋巴瘤（DLBCL）风险增加相关（OR：1.83，95%CI：1.15-2.91），病例组和对照组的检测阳性率分别为19.7%和12.2%。抗ENA或抗dsDNA的存在与NHL风险增加相关（OR：2.93，95%CI：1.18-7.28），尤其是DLBCL（OR：3.51，95%CI：1.02-12.0）和边缘区淋巴瘤（OR：8.86，95%CI：1.26-62.0）。我们的研究表明，自身抗体与DLBCL风险升高相关，为自身免疫作为一个风险因素提供了支持。
